WO2022225119A1 - Composition cosmétique anti-inflammatoire et son procédé de préparation - Google Patents

Composition cosmétique anti-inflammatoire et son procédé de préparation Download PDF

Info

Publication number
WO2022225119A1
WO2022225119A1 PCT/KR2021/016797 KR2021016797W WO2022225119A1 WO 2022225119 A1 WO2022225119 A1 WO 2022225119A1 KR 2021016797 W KR2021016797 W KR 2021016797W WO 2022225119 A1 WO2022225119 A1 WO 2022225119A1
Authority
WO
WIPO (PCT)
Prior art keywords
weight
cosmetic composition
parts
extract
inflammatory
Prior art date
Application number
PCT/KR2021/016797
Other languages
English (en)
Korean (ko)
Inventor
이기훈
Original Assignee
주식회사 오투네이쳐
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 오투네이쳐 filed Critical 주식회사 오투네이쳐
Publication of WO2022225119A1 publication Critical patent/WO2022225119A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures
    • A61K2800/592—Mixtures of compounds complementing their respective functions
    • A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/82—Preparation or application process involves sonication or ultrasonication

Definitions

  • the present invention relates to an anti-inflammatory cosmetic composition and a method for manufacturing the same, and more particularly, to an anti-inflammatory cosmetic composition capable of improving the anti-inflammatory effect by adjusting the components and content contained in the cosmetic composition, and a method for preparing the same.
  • Oxygen in a stable state in the human body is a highly reactive reactive oxygen species such as superoxide anion radical, hydrogen peroxide radical, and singlet oxygen through biochemical mechanisms. ) is converted to
  • Superoxide radical anion (O 2 - ⁇ ), hydrogen peroxide (H 2 O 2 ), hydroxy radical generated during normal intracellular activity in vivo or generated by environmental pollution or exposure to chemicals (hydroxylradicals, ⁇ OH) are called reactive oxygen species (ROS).
  • Active oxygen means oxygen with free radicals, has an unstable nature, and is known to cause oxidative stress in cells because of its strong reactivity with surrounding substances.
  • Free radicals such as superoxide anion radicals, hydrogen peroxide radicals, and singlet oxygen promote oxidation in vivo and cause peroxidation of unsaturated fatty acids in phospholipids to enhance cell membrane permeability and cause cytotoxicity, leading to aging, inflammation and various induce the pathology of the disease.
  • ROS reactive oxygen species
  • the present invention provides a composition and a method for preparing the same, which can be used as a cosmetic to prevent skin aging while improving the anti-inflammatory effect by controlling the components included in the plant complex extract.
  • Patent Document 1 Korean Patent Publication No. 2006-0127405
  • the technical problem to be achieved by the present invention is to provide an anti-inflammatory cosmetic composition capable of improving the anti-inflammatory effect by controlling the components and content of the extract included in the cosmetic composition, and a method for preparing the same.
  • An exemplary embodiment of the present invention is Angelicasinensis ), peppermint ( Mentha arvensis var. piperascens ), upper leaves ( Morusalba leaves ), bamboo leaves ( Sasa borealis ), gardenia ( Gardeniae Fructus ) Plant complex extract comprising an extract extracted from each dried product It provides an anti-inflammatory cosmetic composition comprising as an active ingredient.
  • the extract may be extracted with an extraction solvent selected from the group consisting of water, an organic solvent, and a mixed solvent thereof.
  • the organic solvent may be one selected from the group consisting of alcohols having 1 to 4 carbon atoms, ethyl acetate, glycerol, ethylene glycol, propylene glycol, butylene glycol, and combinations thereof.
  • the Angelica root extract may be extracted from the dried Angelica plant in an amount of 50 parts by weight or more and 200 parts by weight or less with respect to 100 parts by weight of the dried gardenia plant.
  • the mint extract may be extracted from the dried mint in an amount of 150 parts by weight or more and 250 parts by weight or less based on 100 parts by weight of the dried gardenia.
  • the upper leaf extract may be extracted from the dried upper leaf in an amount of 50 parts by weight or more and 150 parts by weight or less based on 100 parts by weight of the dried gardenia.
  • the bamboo leaf extract may be extracted from the dried bamboo leaves in an amount of 150 parts by weight or more and 250 parts by weight or less based on 100 parts by weight of the dried gardenia.
  • it may further include water, and the content of the plant complex extract may be 1% by weight or more and 10% by weight or less.
  • it may further include a cosmetic base composition.
  • One embodiment of the present invention is in the method for preparing the anti-inflammatory cosmetic composition, Angelicasinensis , peppermint ( Mentha arvensis var. piperascens ), upper leaf ( Morusalba leaves ), bamboo leaf ( Sasa borealis ), gardenia ( GardeniaeFructus ) preparing each mixture by mixing each dried product with an extraction solvent; heating each mixture to extract each extract; preparing a plant complex extract by mixing the respective extracts; and mixing the plant complex extract with a cosmetic base composition to provide a method for producing a cosmetic composition for anti-inflammatory comprising the step of preparing a cosmetic composition.
  • the temperature of the heating step may be 40 °C or more and 80 °C or less.
  • the heating step may be applying an ultrasonic wave of 700 kHz or more and 1,200 kHz or less.
  • the anti-inflammatory cosmetic composition according to an exemplary embodiment of the present invention can improve the anti-inflammatory effect.
  • the method for producing a cosmetic composition for anti-inflammatory can easily prepare the cosmetic composition while maximizing the anti-inflammatory effect implemented in the cosmetic.
  • FIG. 1 is a flowchart of a method for manufacturing an anti-inflammatory cosmetic composition according to an exemplary embodiment of the present invention.
  • Example 2 is a graph showing the relative comparison of cell viability according to the amount of sample added in Example.
  • 3 is a graph showing the generation amount of inflammatory cytokines according to the sample addition amount of Example.
  • the unit “part by weight” may mean a ratio of weight between each component.
  • a and/or B means “A and B, or A or B.”
  • extract includes all substances obtained by extracting components therein from natural products, irrespective of the extraction method or types of components. For example, it may mean extracting a component soluble in a solvent from a natural product using water or an organic solvent.
  • An exemplary embodiment of the present invention is Angelicasinensis ), peppermint ( Mentha arvensis var. piperascens ), upper leaves ( Morusalba leaves ), bamboo leaves ( Sasa borealis ), gardenia ( Gardeniae Fructus ) Plant complex extract comprising an extract extracted from each dried product It provides an anti-inflammatory cosmetic composition comprising as an active ingredient.
  • the anti-inflammatory cosmetic composition according to an exemplary embodiment of the present invention can improve the anti-inflammatory effect.
  • the anti-inflammatory cosmetic composition includes an extract extracted from a dried product of Angelicasinensis .
  • Angelicasinensis is a perennial plant belonging to the Asteraceae family, and the root is used as a medicine in oriental medicine.
  • Angelica is effective for people who do not have blood on their face, often get dizziness, and do not have gloss on their eyes and lips because it has the effect of blood. Therefore, Angelica is often used for various diseases before or after childbirth, as it has excellent efficacy in controlling headaches and menstruation in women due to weakness in the body, and treats menstrual irregularities and abdominal pain. In addition, it is effective in treating constipation due to weak stomach function.
  • the anti-inflammatory cosmetic composition contains an extract extracted from the dried Angelica fruit, it is possible to alleviate inflammation occurring in the body.
  • the anti-inflammatory cosmetic composition includes an extract extracted from the dried matter of mint ( Mentha arvensis var. piperascens ).
  • peppermint Mentha arvensis var. piperascens
  • the main ingredients of mint are alpha-pinene (+, -), anisaldehyde, Daucosterol, Eugenol, Linalool, Menthone, (+)-Neomenthol ((+)-Neomenthol) and the like.
  • Mint emits a refreshing and refreshing scent, and has sterilizing and antibacterial action against pathogenic fungi, Escherichia coli, and Staphylococcus aureus that cause eczema and scabies on the skin and scalp.
  • the anti-inflammatory cosmetic composition contains the extract extracted from the dried mint of mint, it is possible to improve the sterilization and antibacterial action of the cosmetic composition, thereby alleviating inflammation occurring in the body.
  • the anti-inflammatory cosmetic composition includes an extract extracted from the dried material of Morusalba leaves .
  • "upper leaf” refers to the leaves of Morusalba leaves
  • oriental medicine may refer to drugs obtained by drying the leaves of Morusalba leaves.
  • the upper leaves are used in folk remedies to treat various diseases such as beriberi, edema, and diabetes. show the effect.
  • the anti-inflammatory cosmetic composition includes an extract extracted from the dried matter of the upper leaf, thereby improving the antibacterial activity of the cosmetic composition, thereby alleviating inflammation occurring in the body or skin.
  • the anti-inflammatory cosmetic composition includes an extract extracted from the dried matter of bamboo leaves ( Sasa borealis ).
  • the bamboo leaf ( Sasa borealis ) is a dried leaf of chamdae (or royal daisy), which is bitter in taste and has the effect of lowering body heat as a cold medicine.
  • the bitter and cold nature of bamboo leaves lowers heat in the heart and lungs, and the spicy taste disturbs the wind and heat of the sage and prevents hair loss due to stress in the body.
  • the cosmetic composition lowers the heat of the skin to prevent the inflammation occurring in the skin from worsening.
  • the anti-inflammatory cosmetic composition includes an extract extracted from a dried product of Gardeniae Fructus .
  • "Gardenia ( GardeniaeFructus )” is a plant belonging to the family Rubiaceae, and the main components are Crocin, Crocetin, Gardonin, Genipin, Geniposide, etc.
  • the yellow pigment contains components such as alpha crochin, xanthyltin, psoralen, fauchedanolmethyl, and esters.
  • Gardenia is used in folk remedies for bruises and wounds, and it is effective for fever, cough, anti-inflammatory, hematemesis, hemoptysis, and jaundice.
  • the anti-inflammatory cosmetic composition includes an extract extracted from the dried matter of Gardeniae Fructus , it is possible to minimize inflammation in the skin due to the anti-inflammatory effect.
  • the anti-inflammatory cosmetic composition is Angelicasinensis extract, peppermint ( Mentha arvensis var. piperascens ) extract, upper leaf ( Morusalba leaves ) extract, bamboo leaf ( Sasa borealis ) extract, gardenia ( GardeniaeFructus ) plant complex extracts including extracts.
  • the anti-inflammatory cosmetic composition is Angelicasinensis extract, peppermint ( Mentha arvensis var. piperascens ) extract, upper leaf ( Morusalba leaves ) extract, bamboo leaf ( Sasa borealis ) extract, gardenia ( GardeniaeFructus ) plant complex extracts including extracts.
  • the anti-inflammatory cosmetic composition is Angelicasinensis extract, peppermint ( Mentha arvensis var.
  • the anti-inflammatory cosmetic composition may further include one selected from the group consisting of maekmundong extract, mokdanpi extract, cornflower extract, self-inflicted extract, cheonmundong extract, hwangbaek extract, and combinations thereof.
  • the extract may be extracted with an extraction solvent selected from the group consisting of water, an organic solvent, and a mixed solvent thereof.
  • an extraction solvent selected from the group consisting of water, an organic solvent, and a mixed solvent thereof.
  • the organic solvent may be one selected from the group consisting of alcohols having 1 to 4 carbon atoms, ethyl acetate, glycerol, ethylene glycol, propylene glycol, butylene glycol, and combinations thereof.
  • the alcohol having 1 to 4 carbon atoms may be methanol, ethanol, propanol or butanol.
  • the Angelica root extract may be extracted from the dried Angelica root in an amount of 50 parts by weight or more and 200 parts by weight or less based on 100 parts by weight of the dried gardenia.
  • the Angelica extract is 60 parts by weight or more and 190 parts by weight or less, 70 parts by weight or more and 180 parts by weight or less, 80 parts by weight or more and 170 parts by weight or less, 90 parts by weight or more and 160 parts by weight or less, based on 100 parts by weight of the dried gardenia.
  • 100 parts by weight or more and 150 parts by weight or less, 110 parts by weight or more and 140 parts by weight or less, or 120 parts by weight or more and 130 parts by weight or less may be extracted from the dried angelfish.
  • the Angelica basil extract is extracted from the dried Angelica basil in 130 parts by weight based on 100 parts by weight of the dried gardenia.
  • the mint extract may be extracted from the dried mint in an amount of 150 parts by weight or more and 250 parts by weight or less based on 100 parts by weight of the dried gardenia.
  • the mint extract is contained in an amount of 160 parts by weight or more and 240 parts by weight or less, 170 parts by weight or more and 230 parts by weight or less, 180 parts by weight or more and 220 parts by weight or less, or 190 parts by weight or more and 210 parts by weight or less with respect to 100 parts by weight of the dried gardenia.
  • It may be extracted from the dried mint. More specifically, the mint extract is preferably extracted from the dried mint in an amount of 200 parts by weight or less based on 100 parts by weight of the dried gardenia.
  • the upper leaf extract may be extracted from the dried upper leaves in an amount of 50 parts by weight or more and 150 parts by weight or less based on 100 parts by weight of the dried gardenia.
  • the upper leaf extract contains 60 parts by weight or more and 140 parts by weight or less, 70 parts by weight or more and 130 parts by weight or less, 80 parts by weight or more and 120 parts by weight or less, or 90 parts by weight or more and 110 parts by weight or less with respect to 100 parts by weight of the dried gardenia. It may be extracted from the dried upper leaves. More specifically, it is preferable that the upper leaf extract is extracted from the dried upper leaf in 100 parts by weight based on 100 parts by weight of the dried gardenia.
  • the bamboo leaf extract may be extracted from the dried bamboo leaves in an amount of 150 parts by weight or more and 250 parts by weight or less based on 100 parts by weight of the dried gardenia.
  • the bamboo leaf extract is present in an amount of 160 parts by weight or more and 240 parts by weight or less, 170 parts by weight or more and 230 parts by weight or less, 180 parts by weight or more and 220 parts by weight or less, or 190 parts by weight or more and 210 parts by weight or less with respect to 100 parts by weight of the dried gardenia.
  • It may be extracted from the dried bamboo leaves. More specifically, the bamboo leaf extract is preferably extracted from the dried bamboo leaf in 200 parts by weight based on 100 parts by weight of the dried gardenia.
  • the anti-inflammatory cosmetic composition may further include water.
  • the concentration of the anti-inflammatory cosmetic composition can be adjusted, and the content of the active ingredient in the anti-inflammatory cosmetic composition can be adjusted to maximize the inflammation relief effect.
  • the content of the plant complex extract in the anti-inflammatory cosmetic composition may be 1% by weight or more and 10% by weight or less.
  • the content of the plant complex extract in the anti-inflammatory cosmetic composition is 2 wt% or more and 9 wt% or less, 3 wt% or more and 8 wt% or less, 4 wt% or more and 7 wt% or less, or 5 wt% or more and 6 wt% may be below.
  • the anti-inflammatory cosmetic composition may further include a cosmetic base composition.
  • the anti-inflammatory cosmetic composition may further include one selected from the group consisting of a cosmetic base composition, such as essence, cream, lotion, toner, and combinations thereof.
  • a cosmetic base composition such as essence, cream, lotion, toner, and combinations thereof.
  • One embodiment of the present invention is in the method for preparing the anti-inflammatory cosmetic composition, Angelicasinensis , peppermint ( Mentha arvensis var. piperascens ), upper leaf ( Morusalba leaves ), bamboo leaf ( Sasa borealis ), gardenia ( GardeniaeFructus ) preparing each mixture by mixing each dried product with an extraction solvent; heating each mixture to extract each extract; preparing a plant complex extract by mixing the respective extracts; and mixing the plant complex extract with a cosmetic base composition to provide a method for producing a cosmetic composition for anti-inflammatory comprising the step of preparing a cosmetic composition.
  • the method for producing a cosmetic composition for anti-inflammatory can easily prepare the cosmetic composition while maximizing the anti-inflammatory effect implemented in the cosmetic.
  • FIG. 1 is a flowchart of a method for manufacturing an anti-inflammatory cosmetic composition according to an exemplary embodiment of the present invention.
  • a method of manufacturing the anti-inflammatory cosmetic composition of the present invention will be described with reference to FIG. 1 .
  • a portion overlapping with the description of the anti-inflammatory cosmetic composition will be omitted.
  • Angelicasinensis Mentha arvensis var. piperascens
  • upper leaves Morusalba leaves
  • bamboo leaves Sasa borealis
  • gardeniae Gardeniae Fructus
  • the present invention includes the step of extracting each extract by heating each of the mixtures (S30). It is possible to efficiently extract the active ingredients contained in each of the dried substances. As described above, by extracting each extract by heating each mixture as described above, the inflammatory effect can be maximized by extracting at a suitable temperature so that the active ingredient of each dried product is not denatured.
  • it includes the step (S50) of preparing a plant complex extract by mixing each of the extracts.
  • step (S50) of preparing a plant complex extract by mixing each of the extracts By preparing a plant complex extract by mixing the respective extracts as described above, the components in the plant complex extract do not react with each other and the active ingredients are maintained and compatibility can be improved.
  • a plant complex extract can be prepared by preparing a dry mixture of Angelica basil, dried mint, dried upper leaves, dried bamboo leaves, and dried gardenia, and heating the dried mixture.
  • a mixture of dry matter in which all of the dry matter is mixed and heating it to prepare a plant complex extract it is possible to provide a manufacturing method suitable for mass production by shortening the manufacturing time of the plant complex extract.
  • a step (S70) of preparing a cosmetic composition by mixing the plant complex extract with a cosmetic base composition is included.
  • a cosmetic with improved anti-inflammatory effect can be prepared.
  • the temperature of the heating step may be 40 °C or more and 80 °C or less.
  • the temperature of the heating step is 41 °C or more and 79 °C or less, 42 °C or more and 78 °C or less, 43 °C or more and 77 °C or less, 44 °C or more and 76 °C or less, 45 °C or more and 75 °C or less, 46 °C or more and 74 °C or less.
  • the temperature of the heating step is preferably 50 °C By controlling the temperature of the heating step in the above-mentioned range, it is possible to prevent deterioration of each extract and at the same time maximize the extraction efficiency of the active ingredient.
  • the heating step may be applying an ultrasonic wave of 700 kHz or more and 1,200 kHz or less.
  • ultrasonic waves of 750 kHz or more and 1,150 kHz or less, 800 kHz or more and 1,100 kHz or less, 850 kHz or more and 1,050 kHz or less, or 900 kHz or more and 1,000 kHz or less may be applied.
  • the frequency of the ultrasonic wave applied in the heating step in the above range, it is possible to maximize the extraction efficiency of the active ingredient extracted from the dried material.
  • the heating step may be performed for 24 hours or more and 96 hours or less. Specifically, 25 hours or more and 95 hours or less, 30 hours or more and 90 hours or less, 35 hours or more and 85 hours or less, 40 hours or more and 80 hours or less, 45 hours or more and 75 hours or less, 50 hours or more and 70 hours or less, or 55 hours or more and 65 hours or less. may be performed with More specifically, the heating step is preferably performed for 72 hours. By controlling the execution time of the heating step in the above-described range, it is possible to maximize the extraction efficiency without alteration of the active ingredient.
  • each extract was mixed to prepare a solution containing the plant complex extract, and then water was added to the plant complex extract to prepare an anti-inflammatory cosmetic composition having a concentration of about 5%.
  • the anti-inflammatory cosmetic composition was dried at -80 ° C. in a freeze dryer (FD8508S, Busan, Korea) for 3 days and then used.
  • the dried sample was dissolved in distilled dimethyl sulfoxide (DMSO) and sterilized by passing through a 0.22 ⁇ m syringe filter (Millipore, MA, USA).
  • DMSO dimethyl sulfoxide
  • RAW264.7 cells were heat-inactivated at 5% CO 2 , 37° C. with heat-inactivated fetal bovine serum (FBS), 100 U/ml penicillin, and 100 ⁇ g/ml streptomycin (streptomycin, Invitrogen). , Carlsbad, CA, America) supplemented with high glucose DMEM (Dulbecco's modified Eagle's medium).
  • FBS heat-inactivated fetal bovine serum
  • penicillin 100 U/ml penicillin
  • streptomycin streptomycin, Invitrogen
  • Carlsbad, CA, America supplemented with high glucose DMEM (Dulbecco's modified Eagle's medium).
  • Example sample After culturing RAW264.7 cells seeded in the 96-well plate for one day, the plate to which the sample prepared in Example was not added and the sample prepared in Example (hereinafter referred to as “Example sample”) were 10 Each plate treated with ⁇ g/ml, 100 ⁇ g/ml and 1000 ⁇ g/ml was incubated for 24 hours. After incubation, 50 ⁇ l of 2,3-Bis (2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) solution was treated and incubated again for 4 hours.
  • XTT 2,3-Bis (2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide
  • the absorbance was repeatedly measured at 450 nm with a microplate reader (Molecular Devices, Sunnyvale, CA, USA) three times and summarized in Table 1 below, and the average of the values obtained by measuring the absorbance of the Example sample in Table 1 divided by % and summarized in Table 2.
  • Example sample unadded plate (NC) 91.54164 102.4569 106.0015 100 7.536515 -
  • Example sample 10 ⁇ g/ml addition plate (10 ⁇ g/ml) 91.42911 103.4696 99.81245 98.23706 6.172914 0.76961
  • Example sample 100 ⁇ g/ml addition plate (100 ⁇ g/ml) 94.86122 99.30608 100.7408 98.3027 3.065531 0.736131
  • Example sample 1000 ⁇ g/ml addition plate (1000 ⁇ g/ml) 88.86909 97.16804 92.75131 92.92948 4.152343 0.227758
  • Example 2 is a graph showing the relative comparison of cell viability according to the amount of sample added in Example. Referring to Table 1 and Table 2 and FIG. 2, when a toxic XTT solution is added to a plate in which RAW264.7 cells are cultured, absorbance is maintained even when the sample prepared in Example is added. It was confirmed that the Example sample was non-toxic.
  • RAW264.7 cells were heat-inactivated at 5% CO 2 , 37° C. with heat-inactivated fetal bovine serum (FBS), 100 U/ml penicillin, and 100 ⁇ g/ml streptomycin (streptomycin, Invitrogen). , Carlsbad, CA, America) supplemented with high glucose DMEM (Dulbecco's modified Eagle's medium).
  • FBS heat-inactivated fetal bovine serum
  • penicillin 100 U/ml penicillin
  • streptomycin streptomycin, Invitrogen
  • Carlsbad, CA, America supplemented with high glucose DMEM (Dulbecco's modified Eagle's medium).
  • the samples prepared in Examples were treated at concentrations of 10 ⁇ g/ml, 100 ⁇ g/ml and 1000 ⁇ g/ml, respectively. After 1 hour, it was treated with LPS (Lipopolysaccharide) 1ug/ml and cultured for 23 hours, and the supernatant was recovered. The supernatant was reacted with IL-1 ⁇ , IL-6, TNF- ⁇ mouse elisa kit (koma biotech. korea), and absorbance was measured at 450 nm with a microplate reader (Molecular Devices, Sunnyvale, CA, USA), and summarized in Table 3. , The concentrations of each of IL-1 ⁇ , IL-6, and TNF- ⁇ were measured from the supernatant and summarized in Table 4.
  • LPS Lipopolysaccharide
  • Example 3 is a graph showing the generation amount of inflammatory cytokines according to the sample addition amount of Example. Referring to Tables 3 and 4 and FIG. 3, it was confirmed that the Example sample inhibited inflammatory cytokines (IL-1 ⁇ , IL-6, TNF- ⁇ ) in a concentration-dependent manner as a result of measurement of inflammatory cytokines using macrophages. .
  • the anti-inflammatory cosmetic composition and the method for preparing the same can improve the anti-inflammatory effect and facilitate the anti-inflammatory effect by controlling the components included in the cosmetic composition and at the same time adjusting the ratio thereof. It was confirmed that a cosmetic composition can be prepared.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une composition cosmétique anti-inflammatoire et son procédé de préparation et, plus précisément, une composition cosmétique anti-inflammatoire renfermant des ingrédients et un contenu contrôlés pour présenter des effets anti-inflammatoires améliorés, et son procédé de préparation.
PCT/KR2021/016797 2021-04-20 2021-11-16 Composition cosmétique anti-inflammatoire et son procédé de préparation WO2022225119A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2021-0051045 2021-04-20
KR1020210051045A KR102323878B1 (ko) 2021-04-20 2021-04-20 항염증용 화장료 조성물 및 그의 제조방법

Publications (1)

Publication Number Publication Date
WO2022225119A1 true WO2022225119A1 (fr) 2022-10-27

Family

ID=78610380

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2021/016797 WO2022225119A1 (fr) 2021-04-20 2021-11-16 Composition cosmétique anti-inflammatoire et son procédé de préparation

Country Status (2)

Country Link
KR (2) KR102323878B1 (fr)
WO (1) WO2022225119A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102323878B1 (ko) * 2021-04-20 2021-11-09 주식회사 오투네이쳐 항염증용 화장료 조성물 및 그의 제조방법
CN114425029B (zh) * 2022-02-14 2024-05-10 西安绿天生物技术有限公司 具有抗炎舒敏的植物提取组合物、制备方法及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110134719A (ko) * 2010-06-09 2011-12-15 (주)파이토니아 화장품 조성물 및 피부 외용제 조성물
KR101894175B1 (ko) * 2017-01-17 2018-08-31 대전대학교 산학협력단 프로폴리스, 모링가 및 상엽 혼합 추출물을 유효성분으로 함유하는 화장료 조성물
KR20190086317A (ko) * 2018-01-12 2019-07-22 김유근 한방 복합추출물을 포함하는 아토피 피부염 예방 또는 개선용 조성물
KR102108912B1 (ko) * 2019-04-18 2020-05-11 이에스더 한약재 발효분말이 함유된 피부보습 및 염증 개선용 조성물
KR102323878B1 (ko) * 2021-04-20 2021-11-09 주식회사 오투네이쳐 항염증용 화장료 조성물 및 그의 제조방법

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110134719A (ko) * 2010-06-09 2011-12-15 (주)파이토니아 화장품 조성물 및 피부 외용제 조성물
KR101894175B1 (ko) * 2017-01-17 2018-08-31 대전대학교 산학협력단 프로폴리스, 모링가 및 상엽 혼합 추출물을 유효성분으로 함유하는 화장료 조성물
KR20190086317A (ko) * 2018-01-12 2019-07-22 김유근 한방 복합추출물을 포함하는 아토피 피부염 예방 또는 개선용 조성물
KR102108912B1 (ko) * 2019-04-18 2020-05-11 이에스더 한약재 발효분말이 함유된 피부보습 및 염증 개선용 조성물
KR102323878B1 (ko) * 2021-04-20 2021-11-09 주식회사 오투네이쳐 항염증용 화장료 조성물 및 그의 제조방법

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SONG, WON-YOUNG; BYEON, SO-JEONG; CHOI, JEONG-HWA: "Anti-oxidative and Anti-inflammatory Activities of Sasa borealis Extracts", JOURNAL OF AGRICULTURE & LIFE SCIENCES - NONG'EOB SAENGMYEONG GWAHAG YEON'GU, GYEONGSANG DAEHAKGYO, NONG-EOP SAENGMYEONG GWAHAG YYEON-GUWON,GYEONGSANG NATIONAL UNIVERSITY, INSTITUTE OF AGRICULTURE AND LIFE SCIENCES, KOREA, vol. 49, no. 3, 1 January 2015 (2015-01-01), Korea, pages 145 - 154, XP009540646, ISSN: 1598-5504, DOI: 10.14397/jals.2015.49.3.145 *

Also Published As

Publication number Publication date
KR20220144748A (ko) 2022-10-27
KR102323878B1 (ko) 2021-11-09

Similar Documents

Publication Publication Date Title
WO2022225119A1 (fr) Composition cosmétique anti-inflammatoire et son procédé de préparation
WO2023074990A1 (fr) Procédé de préparation d'une composition cosmétique dépilatoire facile à préparer en formulations présentant diverses viscosités
WO2022177215A1 (fr) Procédé pour favoriser l'activité antioxydante de feuilles de thé pourpre
CN112006970B (zh) 一种抗瘙痒功效组合物及其制备方法与应用
KR101716489B1 (ko) 상동나무 추출물을 함유하는 화장료 조성물
WO2019088446A1 (fr) Composition d'atténuation des dégâts causés aux cellules cutanées humaines provoqués par les rayons ultraviolets, contenant un extrait d'hydrangea serrata
KR20140126892A (ko) 진세노사이드 Rg3를 함유하는 피부 외용제 조성물
KR101458887B1 (ko) 히카마, 콜리플라워, 말로우 및 아이슬란드 이끼 천연 복합추출물을 유효성분으로 함유하는 항산화, 보습, 피부 자극 완화 효과를 갖는 피부 개선용 화장료 조성물
KR101944025B1 (ko) 하늘타리 추출물을 유효성분으로 함유하는 안티폴루션 화장료 조성물
Picerno et al. An extract of Lannea microcarpa: composition, activity and evaluation of cutaneous irritation in cell cultures and reconstituted human epidermis
KR20170112745A (ko) 티트리 잎 미세침 분말을 함유하는 여드름 개선용 화장료 조성물
KR102092177B1 (ko) 브로콜리 추출물을 유효성분으로 함유하는 안티폴루션 화장료 조성물
KR102300581B1 (ko) 식물추출물 또는 이의 분획물을 유효성분으로 함유하는 피부 상태 개선용 조성물
WO2013077569A1 (fr) Composition de traitement cutané à application topique comprenant un extrait de dendranthema indicum
KR102189415B1 (ko) 대황 추출물을 유효성분으로 포함하는 자외선에 의한 피부 손상 예방 또는 개선을 위한 조성물
KR20110092856A (ko) 피부 주름 개선용 화장료 조성물
WO2013115456A1 (fr) Aliment, substance cosmétique, ou composition pharmaceutique contenant un extrait supercritique de gingembre et un extrait de résidu de persil japonais fermenté
KR20190062157A (ko) 피지 조절 및 모공 축소용 조성물
KR101303807B1 (ko) 항노화 화장료 조성물
KR20170101342A (ko) 피부의 열을 조절해주는 천연 식물 혼합 추출물 및 이를 함유하는 피부 열노화 억제용 화장료 조성물
ES2962832T3 (es) Tratamiento de la piel envejecida o dañada por UV
US20240075089A1 (en) Botanicals as wnt/beta-catenin activators, molecular pathway regulators, tissue regenerators and health biomarker regulators
KR20100010315A (ko) 피부 노화 방지 효과를 가지는 생약 화장료 조성물
KR100670237B1 (ko) 홍화씨추출물을 함유하는 화장료 조성물 및 홍화씨 내 화장료 유효성분 추출방법
KR20170045927A (ko) 위릉채 추출물을 함유한 항노화 피부 외용제 조성물 및 그 제조방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21938035

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21938035

Country of ref document: EP

Kind code of ref document: A1